Compare MSAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | SNGX |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 11.2M |
| IPO Year | N/A | 2006 |
| Metric | MSAI | SNGX |
|---|---|---|
| Price | $5.51 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $110.00 | $6.00 |
| AVG Volume (30 Days) | 34.9K | ★ 9.8M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | $98.45 | N/A |
| Revenue Next Year | $38.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.28 |
| 52 Week High | $7.20 | $6.23 |
| Indicator | MSAI | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 54.74 |
| Support Level | $5.40 | $0.28 |
| Resistance Level | $6.92 | $1.48 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 6.67 | 53.81 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).